StreetAccount Summary - Private Company Weekly Recap - Week of 2-Nov
StreetAccount China Pre Market Update: China ADRs overnight +1.67%; Hang Seng Futures (0.88%)
Sino Biopharmaceutical presents TQ-A3334 phase II hepatitis B study at AASLD (HK$5.60, 0.00)
StreetAccount Sector Summary - China Healthcare October Recap
StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning
StreetAccount China Pre Market Update: China ADRs overnight +3.49%; Hang Seng Futures +4.46%
Powered by FactSet Research Systems Inc.